Kronos Bio (NASDAQ:KRON) Cut to “Hold” at TD Cowen

TD Cowen downgraded shares of Kronos Bio (NASDAQ:KRON) from a buy rating to a hold rating in a report issued on Thursday morning, Marketbeat reports.

A number of other equities analysts have also weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price on shares of Kronos Bio in a research report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $2.25 target price on shares of Kronos Bio in a research report on Monday, August 19th.

Kronos Bio Price Performance

Shares of KRON opened at $0.85 on Thursday. Kronos Bio has a 52-week low of $0.69 and a 52-week high of $1.60. The business’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $1.03.

Institutional Investors Weigh In On Kronos Bio

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Kronos Bio by 14.6% during the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after buying an additional 247,918 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Kronos Bio by 17.2% during the first quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock worth $1,005,000 after buying an additional 113,618 shares in the last quarter. Forefront Analytics LLC grew its holdings in Kronos Bio by 75.0% during the second quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock worth $167,000 after buying an additional 57,867 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Kronos Bio during the first quarter worth $71,000. Institutional investors own 64.09% of the company’s stock.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.